Pharmaceutical innovation is at a critical inflection point. Most companies are investing in groundbreaking science – but they’re neglecting to evolve the fragile business models around it.

That’s the argument from Elliott Parker, CEO of Alloy Partners, a venture studio that helps corporations create startups to drive strategic innovation. With experience building pharma ventures like Revisto (backed by Eli Lilly) and advising Fortune 500 companies at Clayton Christensen’s Innosight, Parker believes traditional models of R&D and internal innovation are no longer enough.

“Pharma companies are great at product innovation,” he says. “They find breakthrough molecules and are excellent at running them through their existing business model to commercialize them. But that underlying business model – which evolved slowly over decades – is fragile. It’s vulnerable to rapid disruption from regulatory, technological, or competitive changes.”

According to Parker, the industry urgently needs to apply the same rigor used in lab experiments to its approach to business model innovation.

“Pharma companies should be running business model experiments to uncover new, better ways of operating – just like they run experiments to discover molecules.”

Why traditional R&D clashes with agile innovation

The conventional R&D pipeline, with its extended timelines and siloed development, can stifle new thinking. In contrast, venture building offers an agile alternative.

“Agile experimentation allows pharma to explore business models that would be too difficult or time-consuming to investigate using traditional methods,” Parker explains. “It broadens the innovation potential beyond the limitations of in-house R&D.”

When large companies partner with venture studios like Alloy Partners, they see benefits like accelerated development timelines and reduced administrative complexity – making the cultural shift less daunting over time.

Managing regulatory risk while moving fast

In a risk-averse, highly regulated industry, many executives struggle to reconcile the need for speed with compliance. Parker argues that the answer lies in building external, venture-backed startups that are purpose-built to move fast.

“Venture building is a methodical, replicable framework,” he says. “It lets pharma systematically create a more diverse collection of innovative enterprises. These startups – operating independently but backed by the parent organization – can solve real-world problems and bring value to all stakeholders.”

For pharmaceutical companies, the distinction between traditional R&D and technology-driven business model evolution is critical. Venture building provides a structured way to reduce innovation risk while staying competitive.

Unlocking AI by activating internal expertise

As AI dominates headlines, many pharma firms are unsure how to move from hype to meaningful results. Parker sees untapped potential in their internal scientific expertise – if they can connect it to strategic AI initiatives.

“Many companies are stuck in an AI rut because they don’t know where to start,” he says. “A three-pronged approach works best: First, identify AI use cases that solve real problems. Second, establish a solid data infrastructure with governance for compliance. And third, don’t hesitate to bring in strategic partners who specialize in AI.”

By activating domain experts who understand both science and patient needs, pharma companies can begin applying AI in areas like trial optimization and precision medicine – without falling into what Parker calls “AI theater.”

The future belongs to the fast

Parker is clear-eyed about what will separate the winners from the rest in the coming decade.

“Moving fast in pharma doesn’t mean cutting corners – it means partnering with Venture building platforms to identify unmet needs and quickly build businesses to meet them,” he says. “This model expands the organization’s capacity to innovate beyond what’s possible internally.”

With venture studios like Alloy Partners playing an increasingly strategic role in pharma’s transformation, Parker says the industry’s future may depend less on molecules – and more on models.